Some beauty brands talk about “turning back the clock.” OneSkin just went ahead and built the clock themselves. Back in 2016, four Brazilian PhD scientists, Carolina Reis Oliveira, PhD, Alessandra Zonari, PhD, Mariana Boroni, PhD, and Juliana Carvalho, PhD, were running molecular aging tests in a lab when they did something nobody else in skincare had done. They created MolClock, the first skin-specific molecular age test, then used it to screen more than 900 peptides until they landed on OS-01, the first peptide proven to reverse skin’s molecular age by targeting senescent cells. Not “moisturize better.” Not “look refreshed.” Reverse biological age at the cellular level.
Fast forward to August 7, 2025. OneSkin just closed a $20 million Series A led by Prelude Growth Partners, with Selva Ventures, Unilever Ventures, Plus Capital, SOSV, Meta Planet, Able Partners, Camila Alves McConaughey, and Kevin Rose in the mix. Add this to their earlier funding and they are now sitting at $40 million raised, with a growth curve that would make a biotech investor’s pulse race, 150% YoY revenue growth and over 100,000 customers worldwide, from San Francisco to São Paulo to Sydney. Celebrity adopters like Jennifer Aniston, Katy Perry, and Alana Hadid are just the surface layer. The deeper play is their positioning at the intersection of longevity science, dermatology, and consumer beauty.
This round is fuel for a bigger push. They are scaling manufacturing in the US and Europe, expanding retail footprints with partners like Credo Beauty and Violet Grey, and setting up for Asia, Japan and South Korea, before year’s end. They are also expanding the MolClock platform, adding app-based age monitoring, and accelerating AI-driven discovery of the next generation of skin-longevity peptides. The global anti-aging skincare market is an $85 billion arena projected to hit $110 billion by 2028, and OneSkin is not chasing trends, they are setting molecular benchmarks that others will be forced to follow.
For anyone building in biotech or consumer health, there is a clear business takeaway here. Breakthrough science will always attract capital, but only when it is paired with a commercial model that moves units and a narrative that captures imagination. OneSkin did not just publish in npj Aging and hope for the best. They locked in ISO22716 manufacturing, Leaping Bunny certification, strategic distribution intelligence from Unilever Ventures, and a product line that speaks equally to wellness obsessives and dermatology clinics. In an industry obsessed with surface results, they built a company from the cell up. That is not marketing spin. That is the real glow-up.
